The Benefits of Zemaira

CSL Behring is with you every step of the way

Zemaira is approved by the FDA for chronic augmentation and maintenance therapy for adults with Alpha-1 deficiency and emphysema.

Zemaira is there for you every step of the way:

  • Effective – Proven in clinical trials to raise and maintain therapeutic levels of alpha1 antitrypsin
    • Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available
  • Convenient – Low volume of 20 mL requires only 15 minutes to infuse*
  • Purified – The first highly purified alpha1 antitrypsin augmentation therapy approved by the FDA
    • The possibility of transmission of infectious agents cannot be completely eliminated
  • Well-established safety profile – In the clinical trial, the majority of side effects were considered to be mild
To learn more, visit Zemaira.com today.

* Based on recommended dosage, as stated in the product package insert, of 60 mg/kg body weight at an infusion rate of 0.08 mL/kg/min.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Do you want to continue?

No Yes